Search

for
Search:

Did you mean SARS-CoV?

GlossarySARS-CoV

virus causing severe respiratory illness, identified in 2003

SARS-CoV, or Severe Acute Respiratory Syndrome Coronavirus, is a virus that causes a contagious and sometimes fatal respiratory illness. It was first identified in 2003 during an outbreak in Asia and is known for causing severe respiratory symptoms, including fever, cough, and difficulty breathing. SARS-CoV is part of the coronavirus family, which also includes the virus responsible for COVID-19.

Related Terms

Sort by

Community Join

30 / 1000+ results

community Are there a lot of young folks here on fin?

in Chat 3 years ago

Young people who have used finasteride and minoxidil to treat hair loss, with generally positive results reported by those taking the treatments.

community Kintor's KX-826 Phase 2 data release is officially pushed back to September due to COVID:

in Research/Science 15 upvotes 4 years ago

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

community Trial for TDM-105795 update from research office

in Research/Science 17 upvotes 2 years ago

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

community Anagenic is trying to compound Gt20029

in Treatment 56 upvotes 3 years ago

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

community Are we still getting the PP405 phase 2a results by the end of March?

in Research/Science 27 upvotes 3 months ago

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

community 2022 shows much promise so far! No cure in sight, but interesting developments :)

in Research/Science 27 upvotes 4 years ago

Hair loss treatments like GT20029, pyrilutamide, and Follica show promise in 2022. Phase 1 and 2 trials are underway, and new hair growth studies have been published.

community started RU58841 today and am panicing

in Treatment 8 upvotes 2 years ago

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

community Chances of GT20029 hitting the black market?

in Treatment 11 upvotes 2 years ago

The conversation is about the potential availability of GT20029 on the black market and whether users would try it. Participants advise waiting for phase 3 trial results to ensure safety and efficacy.

community Does RU58841 potentially cause cancer?

in Research/Science 1 year ago

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

community GT20029 phase II results release date?

in Research/Science 16 upvotes 2 years ago

The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.

community Where is GT20029 already? Grrrr

in Research/Science 20 upvotes 2 years ago

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

community GT20029 Phase 2 results are out

in Treatment 60 upvotes 6 months ago

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

community redensyl causing a lot of shedding. have bald spots. 1 month redensyl use. thinking of going for CosmeRNA

in Product 2 upvotes 3 years ago

User experienced shedding and bald spots after 1 month of using Redensyl. Considering trying CosmeRNA as alternative treatment.

community Hold up... CosmeRNA/SAMiRNA is actually coming real soon?

in Technology 31 upvotes 3 years ago

A user discovered CosmeRNA, a new hair loss treatment with clinical research backing, set to release soon. The conversation revolves around its potential effectiveness, cost, and how it compares to existing treatments like Minoxidil and Finasteride, with some users expressing hope for a side-effect-free option.

community RU-58841 Lung Disease Possibility | Chest pain, "heart issues", etc

in Treatment 22 upvotes 2 years ago

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

community Looks like Kintor finished enrollment and dosing of phase 1 for gt20029 in China.

in Chat 25 upvotes 3 years ago

The conversation discusses the potential of a new hair loss treatment, GT20029, which targets androgen receptors in the scalp and is in phase 1 trials in China. Users express hope that this treatment will be more effective than current options like Minoxidil and Finasteride.

community bro where tf is GT20029, Q1 2024 is over already

in Research/Science 41 upvotes 2 years ago

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

community Funding for sending RU58841 from rudirect.co.uk to Janoshik Analytical

in Research/Science 11 upvotes 1 year ago

The conversation is about a user trying to fund lab testing for RU58841 to verify its legitimacy, as there are doubts about its effectiveness. Some users express skepticism about RU58841, suggesting alternatives like KX-826.

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 30 upvotes 2 months ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community Kintor Pharma Announces Completion of First Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China.

in Research/Science 129 upvotes 3 years ago

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

community Lyphar Biotech. China source for RU58841

in Research/Science 1 upvotes 3 months ago

The conversation discusses the safety and trustworthiness of ordering RU58841 from Lyphar Biotech in China, with a focus on pricing and reliability. The user is seeking advice on whether to proceed with the purchase or consider alternative sources.

community BREEZULA COVID UPDATE: Filing for Special Protocol Assessment with FDA

in Research/Science 63 upvotes 6 years ago

The conversation discusses the progress of Clascoterone (Breezula) for hair loss treatment, noting that COVID-19 delayed female trials by three months but Phase III trials for males are proceeding with a Special Protocol Assessment filed with the FDA. Users express hope for Breezula as an alternative to existing treatments like finasteride and minoxidil, despite concerns about its potential high cost.

community rudirect ru58841 seems bunk to me

in Treatment 6 upvotes 4 weeks ago

RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.

community Silicon Valley backed company aims to cure hair loss

in Technology 53 upvotes 4 years ago

A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.

community Concerns about CosmeRNA safety mechanisms

in Treatment 3 upvotes 3 years ago

Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.

community Any updates on GT20029? Phase 2 results were supposed to be out by the end of Q1 2024. What happened ?

in Product 20 upvotes 2 years ago

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

community Any updates or news on Gt20029?

in Chat 7 upvotes 1 year ago

There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.

community Dr. Tsuji and Riken to make important announcement on their hair cloning cure on Feb 10th.

in Update 56 upvotes 5 years ago

Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.

community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga

in Technology 9 upvotes 4 months ago

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited

in Research/Science 58 upvotes 3 years ago

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.